

Sinfonia News Release, June 30th , 2022, Stockholm, Sweden



On the annual meeting held on the 30th of June -22, Professor Per Arvidsson and Dr. Olof Larsson were elected new board members

Dr. Olof Larsson has a long and solid background in pain research and has, among other positions, been a global research leader within AstraZeneca for ion channels and pain research.

More recently, Olof was CSO for the Pain and migraine division at Eli Lilly, a world leading company in pain research. Olof's distinguished expertise and broad network within the pain field will be of great benefit for supporting Sinfonia's pain portfolio and progression of SB010 to the market.



Professor Per Arvidsson is a medicinal chemist by training with an extensive scientific and leadership background from both academia and industry. For the past 9 years Per has led the Swedish national Drug Discovery Platform within ScienceForLife (SciLife) laboratories, an organisation which supports the translation of innovative and excellent ideas in the academia towards clinical translational. With his broad experience in drug and biologics discovery, and awareness of new trends and developments within life science, Per will contribute significantly to the success of Sinfonia.

